1.36
price up icon5.38%   0.06
 
loading
Schlusskurs vom Vortag:
$1.30
Offen:
$1.3179
24-Stunden-Volumen:
83,050
Relative Volume:
0.63
Marktkapitalisierung:
$20.71M
Einnahmen:
$1.89M
Nettoeinkommen (Verlust:
$-17.92M
KGV:
-0.2033
EPS:
-6.69
Netto-Cashflow:
$-15.62M
1W Leistung:
+14.17%
1M Leistung:
+2.24%
6M Leistung:
-21.71%
1J Leistung:
-18.45%
1-Tages-Spanne:
Value
$1.295
$1.40
1-Wochen-Bereich:
Value
$1.15
$1.40
52-Wochen-Spanne:
Value
$1.14
$6.40

Longeveron Inc Stock (LGVN) Company Profile

Name
Firmenname
Longeveron Inc
Name
Telefon
305-302-7158
Name
Adresse
1951 NW 7TH AVENUE, MIAMI
Name
Mitarbeiter
25
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
LGVN's Discussions on Twitter

Vergleichen Sie LGVN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
LGVN
Longeveron Inc
1.3598 20.71M 1.89M -17.92M -15.62M -6.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.13 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
527.72 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
319.13 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.82 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.25 28.51B 3.81B -644.79M -669.77M -6.24

Longeveron Inc Stock (LGVN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-06 Eingeleitet ROTH MKM Buy

Longeveron Inc Aktie (LGVN) Neueste Nachrichten

pulisher
Jun 13, 2025

Transcript : Longeveron Inc.Shareholder/Analyst Call - MarketScreener

Jun 13, 2025
pulisher
Jun 10, 2025

Jane Street Group LLC Acquires New Shares in Longeveron Inc. (NASDAQ:LGVN) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - The Manila Times

Jun 09, 2025
pulisher
Jun 09, 2025

Longeveron Inc. CEO Wa’el Hashad to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - Nasdaq

Jun 09, 2025
pulisher
Jun 09, 2025

Exclusive Look: Longeveron CEO Reveals Latest Neuro Therapy Developments at Major Healthcare Conference - Stock Titan

Jun 09, 2025
pulisher
Jun 05, 2025

18,190 Shares in Longeveron Inc. (NASDAQ:LGVN) Bought by Northern Trust Corp - Defense World

Jun 05, 2025
pulisher
Jun 02, 2025

Director’s Major Stock Sale Shakes Up Longeveron! - TipRanks

Jun 02, 2025
pulisher
May 29, 2025

Here's Why Longeveron (NASDAQ:LGVN) Must Use Its Cash Wisely - Yahoo Finance

May 29, 2025
pulisher
May 22, 2025

Q2 Earnings Estimate for Longeveron Issued By HC Wainwright - Defense World

May 22, 2025
pulisher
May 20, 2025

Longeveron Inc. to Explore Partnership Opportunities for Alzheimer’s Stem Cell Therapy Program at BIO International Convention - Nasdaq

May 20, 2025
pulisher
May 20, 2025

Longeveron® to Attend BIO International Convention 2025 - Yahoo Finance

May 20, 2025
pulisher
May 16, 2025

Is Palantir Stock a Buy at All-Time Highs? - The Globe and Mail

May 16, 2025
pulisher
May 12, 2025

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient - GlobeNewswire

May 12, 2025
pulisher
May 12, 2025

Longeveron Inc. Named Top 40 Semifinalist in XPRIZE Healthspan Competition for Stem Cell Therapy Evaluation in Alzheimer’s Disease and HLHS - Nasdaq

May 12, 2025
pulisher
May 11, 2025

Longeveron (LGVN) Projected to Post Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 09, 2025

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update - BioSpace

May 09, 2025
pulisher
May 09, 2025

Longeveron Q1 2025 slides: promising clinical data amid financial headwinds By Investing.com - Investing.com India

May 09, 2025
pulisher
May 09, 2025

Longeveron Reports Q1 2025 Progress and Financials - TipRanks

May 09, 2025
pulisher
May 08, 2025

Earnings call transcript: Longeveron Reports Q1 2025 Results Amid Revenue Decline - Investing.com Canada

May 08, 2025
pulisher
May 07, 2025

Longeveron Inc (LGVN) Q1 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance

May 07, 2025
pulisher
May 03, 2025

Contineum Therapeutics (NASDAQ:CTNM) versus Longeveron (NASDAQ:LGVN) Financial Survey - Defense World

May 03, 2025
pulisher
May 02, 2025

Longeveron Earnings Preview: Latest Updates on Cellular Therapy Pipeline Coming May 8 - Stock Titan

May 02, 2025
pulisher
May 02, 2025

Longeveron Inc. to Report Q1 2025 Financial Results and Business Update on May 8 - Nasdaq

May 02, 2025
pulisher
May 02, 2025

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - The Manila Times

May 02, 2025
pulisher
May 01, 2025

Longeveron Re-approves Cash-to-Equity Program Strategy - TipRanks

May 01, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 22, 2025

Longeveron® Issues Letter to Shareholders Highlighting - GlobeNewswire

Apr 22, 2025
pulisher
Apr 22, 2025

FDA Green Lights Longeveron's Fast-Track Strategy: Key Trials Near Completion for $10B+ Markets - Stock Titan

Apr 22, 2025
pulisher
Apr 10, 2025

Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update - Seeking Alpha

Apr 10, 2025
pulisher
Apr 03, 2025

Where Will Palantir Stock Be in 1 Year? - The Globe and Mail

Apr 03, 2025
pulisher
Mar 28, 2025

Longeveron Files $70 Million Mixed Shelf - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Longeveron Inc Files For Mixed Shelf Of Up To $70 MillionSEC Filing - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Stem Cell Treatment Improves Alzheimer's Symptoms - Newsmax

Mar 28, 2025
pulisher
Mar 23, 2025

Longeveron (NASDAQ:LGVN) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Pharma company behind Alzheimer’s treatment closer to FDA approval - The Business Journals

Mar 21, 2025
pulisher
Mar 20, 2025

FDA aligns with Longeveron on Alzheimer’s therapy trial By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

FDA aligns with Longeveron on Alzheimer’s therapy trial - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Longeveron announces outcome of Type B meeting with FDA on Lomecel-B - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease - The Manila Times

Mar 20, 2025
pulisher
Mar 20, 2025

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

FDA Clears BLA Pathway for Longeveron's Alzheimer's Cell Therapy | LGVN Stock News - Stock Titan

Mar 20, 2025
pulisher
Mar 20, 2025

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Business Wire

Mar 20, 2025
pulisher
Mar 13, 2025

Longeveron's Cell Therapy Lomecel-B Improves Cognitive Function in Mild Alzheimer Disease - CGTLive®

Mar 13, 2025
pulisher
Mar 11, 2025

Laromestrocel shows promise in Alzheimer’s trial By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron® Announces Nature Medicine Publication Of Results Of Phase 2A Clinical Trial Evaluating Laromestrocel (Lomecel-B(TM)) In Alzheimer'S Disease - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Laromestrocel shows promise in Alzheimer’s trial - Investing.com India

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease - The Manila Times

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron announces publication of results of Phase 2a trial of Lomecel-B - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron Inc. Reports Positive Phase 2a Results for Laromestrocel (Lomecel-B™) in Mild Alzheimer’s Disease Treatment - Nasdaq

Mar 11, 2025

Finanzdaten der Longeveron Inc-Aktie (LGVN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Longeveron Inc-Aktie (LGVN) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Soffer Rock
Director
May 29 '25
Sale
1.30
10,000
13,000
220,034
$20.42
price down icon 1.37%
$35.45
price up icon 0.65%
$21.06
price down icon 1.92%
$101.83
price down icon 0.41%
$105.86
price down icon 0.39%
biotechnology ONC
$244.00
price down icon 3.69%
Kapitalisierung:     |  Volumen (24h):